IMVT — Immunovant, Inc. stock price, charts and financials

Latest market price

39.56

-0.39-0.98%

Overview Short InterestFilings

IMVTQT78Immunovant, Inc.·NASDAQ

Overview Short InterestFilings

39.56-0.98%

Loading chart...

Signal & projected range

Earnings big miss — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

ALKS-0.23%$49.05 APGE-0.16%$134.62 PCVX+0.97%$58.63 IBRX-1.31%$7.54 RYTM-0.15%$115.46 KYMR-0.12%$107.39 CRNX+0.17%$84.22 TGTX-1.63%$48.95

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	206.40M	Perf Week	3.44%

Market Cap	8.25B	Forward P/E	-	EPS next Y	-2.69	Insider Trans	-0.34%	Shs Float	79.36M	Perf Month	-2.77%

Enterprise Value	7.45B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	8.60%	Perf Quarter	46.77%

Income	-540.10M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	9.42	Perf Half Y	66.04%

Sales	7.09M	P/B	11.17	EPS next Y	2.30%	ROA	-63.13%	Short Interest	17.76M	Perf YTD	57.16%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-69.59%	52W High	40.83 -3.10%	Perf Year	150.31%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-75.90%	52W Low	14.18 178.98%	Perf 3Y	77.56%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	97.10%	Volatility	3.87% 3.70%	Perf 5Y	281.93%

Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	5.49%	Oper. Margin	-7877.46%	ATR (14)	1.50	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	7.27	Sales Y/Y TTM	-	Profit Margin	-7585.86%	RSI (14)	58.25	Recom	2.26

Dividend Gr. 3/5Y	-	Current Ratio	7.27	EPS Q/Q	3.95%	SMA20	1.60%	Beta	0.80	Target Price	40.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	7.75%	Rel Volume	0.48	Prev Close	39.95

Employees	315	LT Debt/Eq	0.00	Earnings	Nov 18	SMA200	39.73%	Avg Volume	1.71M	Price	39.56

IPO Date	Jun 21, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.31% -	Net Debt/EBITDA	1.48	Volume	812,535	Change	-0.98%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-21-26	Reiterated	HC Wainwright & Co.	Buy	$51 → $40
Jan-06-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$50
Dec-18-25	Reiterated	Guggenheim	Buy	$44 → $41
Oct-14-25	Initiated	Truist	Hold	$16
Apr-22-25	Downgrade	UBS	Buy → Neutral
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-10-24	Reiterated	HC Wainwright & Co.	Buy	$51
Jun-03-24	Reiterated	Oppenheimer	Outperform	$46
May-30-24	Reiterated	Guggenheim	Buy	$48
May-30-24	Reiterated	Piper Sandler	Overweight	$57

Latest News

Aug-06-26

Aug-06-2603:14PM

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcriptseekingalpha.com

03:05PM

Immunovant Q1 Earnings Call Highlightsmarketbeat.com

12:26PM

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progresszacks.com

07:00AM

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026globenewswire.com

Aug-04-26

Aug-04-2602:40PM

JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50Benzinga

Jul-27-26

Jul-27-2611:09PM

Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative BuySeekingAlpha

Jul-21-26

Jul-21-2601:26PM

Tracking Baker Brothers Portfolio: Q1 2026 UpdateSeekingAlpha

Jul-20-26

Jul-20-2605:08PM

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firmglobenewswire.com

Jun-30-26

Jun-30-2602:49PM

Citigroup Maintains Buy on Immunovant, Raises Price Target to $61Benzinga

Company

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2026 3/31/2026	FY 2025 3/31/2025	FY 2024 3/31/2024	FY 2023 3/31/2023	FY 2022 3/31/2022	FY 2021 3/31/2021	FY 2020 3/31/2020	FY 2019 3/31/2019	FY 2018 3/31/2018
Total Revenue	0	0	0	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—	—	—	—	—
Gross Profit	0	0	0	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	76	77	57	—	—	—	—	—	—
Research and Development	457	361	213	—	—	—	—	—	—
Other Operating Expense	0	0	0	—	—	—	—	—	—
Operating Income	-533	-438	-270	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	28	25	11	—	—	—	—	—	—
Net Income Before Taxes	-505	-413	-259	—	—	—	—	—	—
Income Taxes	0	1	1	—	—	—	—	—	—
Consolidated Net Income	-506	-414	-259	—	—	—	—	—	—
Net Income From Continuing Operations	-506	-414	-259	—	—	—	—	—	—
Net Income	-506	-414	-259	—	—	—	—	—	—
EPS (Recurring)	-2.77	-2.73	-1.88	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-2.77	-2.73	-1.88	—	—	—	—	—	—
EPS (Diluted)	-2.77	-2.73	-1.88	—	—	—	—	—	—
EBITDA	-505	-413	-259	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	182	152	138	—	—	—	—	—	—
Market Capitalization	4,521	2,598	4,459	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pande Atul	Director	Jul 24 '26	Sale	39.80	1,500	59,700	116,731	Jul 24
Pande Atul	Director	Jul 24 '26	Option Exercise	8.43	1,500	12,645	118,231	Jul 24
Girao Tiago	Chief Financial Officer	Jul 23 '26	Sale	38.69	6,798	263,015	240,798	Jul 24
Stout Jay S	Chief Technology Officer	Jul 23 '26	Sale	38.69	2,857	110,537	205,341	Jul 24
Stout Jay S	Chief Technology Officer	Jul 08 '26	Sale	39.55	3,487	137,924	208,198	Jul 10
Gloria Melanie	Chief Operating Officer	Jul 08 '26	Sale	39.55	2,036	80,532	222,357	Jul 10
Van Tuyl Christopher	Chief Legal Officer	Jul 08 '26	Sale	39.55	1,206	47,702	179,391	Jul 10
Venker Eric	Chief Executive Officer	Jul 02 '26	Sale	38.48	3,092	118,980	254,280	Jul 06
Venker Eric	Chief Executive Officer	Jul 01 '26	Option Exercise	14.46	92,188	1,333,038	344,001	Jul 06
Van Tuyl Christopher	Chief Legal Officer	Jun 26 '26	Option Exercise	15.20	17,824	270,925	198,421	Jun 26
Gloria Melanie	Chief Operating Officer	Jun 26 '26	Sale	38.31	17,714	678,605	224,393	Jun 26
Stout Jay S	Chief Technology Officer	Jun 26 '26	Sale	38.31	40,000	1,532,310	211,685	Jun 26
Van Tuyl Christopher	Chief Legal Officer	Jun 26 '26	Sale	38.31	17,824	682,887	180,597	Jun 26
Girao Tiago	Chief Financial Officer	Jun 26 '26	Option Exercise	15.90	10,000	159,000	257,596	Jun 26
Girao Tiago	Chief Financial Officer	Jun 26 '26	Sale	38.46	10,000	384,600	247,596	Jun 26

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.